{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:01:47Z","timestamp":1783605707323,"version":"3.55.0"},"reference-count":28,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To compare the efficacy of sodium\u2010glucose cotransporter\u20102 (SGLT2) inhibitors, nonsteroidal mineralocorticoid receptor antagonists (MRAs), selective aldosterone antagonists and nonselective aldosterone antagonists, on top of renin\u2010angiotensin\u2010aldosterone system (RAAS) blockade, in reducing kidney\u2010specific composite events, cardiovascular outcomes, and other events of special interest in participants with type 2 diabetes (T2D) and chronic kidney disease (CKD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, EMBASE and CENTRAL were searched for studies published up to January 20, 2022. Randomized clinical trials enrolling participants with T2D and CKD were included, in which SGLT2 inhibitors, nonsteroidal MRAs, selective aldosterone antagonists and nonselective aldosterone antagonists were compared with either each other, or with placebo or no treatment. A network meta\u2010analysis using a Bayesian approach was performed. The primary outcome was a kidney\u2010specific composite event. Secondary outcomes included death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, and all\u2010cause mortality. We also examined blood pressure and safety outcomes of interest, including acute kidney injury, hyperkalaemia, hyponatraemia, and volume reduction events. All research was conducted according to a protocol registered in the PROSPERO database (CRD42022307113).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This meta\u2010analysis of 17 trials randomizing 22\u2009981 participants found SGLT2 inhibitors (odds ratio [OR] 0.62, 95% confidence interval [CI] 0.52 to 0.73) and nonsteroidal MRAs (OR 0.76, 95% CI 0.66 to 0.88) were associated with significantly lower kidney\u2010specific composite events than the control groups. Nonsteroidal MRAs (OR 0.78, 95% CI 0.66 to 0.92) and SGLT2 inhibitors (OR 0.57, 95% CI 0.45 to 0.72) were associated with greater reductions in hospitalization for heart failure than the control groups. SGLT2 inhibitors were associated with a lower risk of hospitalization for heart failure events compared with nonsteroidal MRAs (OR 0.73, 95% CI 0.55\u20100.97). SGLT2 inhibitors were associated with a reduction in cardiovascular death (OR 0.80, 95% CI 0.65 to 0.98) and all\u2010cause mortality (OR 0.79, 95% CI 0.66 to 0.93) compared with the control groups. When compared to the control groups, both nonsteroidal MRAs (weighted mean difference [WMD] \u221210.96, 95% CI \u221220.49 to \u22121.46) and SGLT2 inhibitors (WMD \u22123.50, 95% CI \u22126.01 to \u22121.013) were linked with lower systolic blood pressure, nonsteroidal MRAs (OR 2.27, 95% CI 2.02 to 2.56) and nonselective aldosterone antagonists (OR 3.22, 95% CI 1.43 to 7.66) were associated with an increased risk of hyperkalaemia, nonsteroidal MRAs were linked with an increased risk of hyponatraemia (OR 16.56, 95% CI 2.78 to 455.19), and SGLT2 inhibitors were associated with an increased risk of volume reduction events (OR 1.28, 95% CI 1.06 to 1.56). SGLT2 inhibitors were ranked the best for our primary and secondary outcomes. Confidence in the evidence was often high or moderate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this network meta\u2010analysis, the use of SGLT2 inhibitors or nonsteroidal MRAs, combined with RAAS blockade, was associated with a reduction in kidney\u2010specific composite events and hospitalization for heart failure events in patients with T2D and CKD compared to placebo or no treatment. SGLT2 inhibitors were associated with a lower risk of hospitalization for heart failure events compared with nonsteroidal MRAs. Use of SGLT2 inhibitors was associated with lower mortality than placebo or no treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14801","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:43:18Z","timestamp":1655433798000},"page":"2159-2168","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Effects of sodium\u2010glucose cotransporter\u20102 inhibitors and aldosterone antagonists, in addition to renin\u2010angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta\u2010analysis"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5253-9188","authenticated-orcid":false,"given":"Shuo","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism The People's Hospital of China Medical University, The People's Hospital of Liaoning Province  Shenyang P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The People's Hospital of China Medical University, The People's Hospital of Liaoning Province  Shenyang P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaochuan","family":"Mi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The People's Hospital of China Medical University, The People's Hospital of Liaoning Province  Shenyang P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism The People's Hospital of China Medical University, The People's Hospital of Liaoning Province  Shenyang P. R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S011"},{"issue":"1","key":"e_1_2_7_3_1","first-page":"S15","article-title":"Standards of medical Care in Diabetes\u20102021","volume":"44","author":"Classification and Diagnosis of Diabetes","year":"2021","journal-title":"Diabetes Care"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30045-6"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30256-6"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.09.011"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190222144359"},{"issue":"2","key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.17925\/EE.2021.17.2.84","article-title":"Finerenone: a potential treatment for patients with chronic kidney disease and type 2 diabetes mellitus","volume":"17","author":"D'Marco L","year":"2021","journal-title":"touchREV Endocrinol"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-019-00600-7"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/snep.2002.35973"},{"key":"e_1_2_7_13_1","first-page":"10","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions","author":"Cumpston M","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.11.021"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0300"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009070737"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"issue":"1","key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"e00303","DOI":"10.1002\/edm2.303","article-title":"Benefits and harms of sodium\u2010glucose co\u2010transporter\u20102 inhibitors (SGLT2\u2010I) and renin\u2010angiotensin\u2010aldosterone system inhibitors (RAAS\u2010I) versus SGLT2\u2010is alone in patients with type 2 diabetes: a systematic review and meta\u2010analysis of randomized controlled trials","volume":"5","author":"Seidu S","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024764"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nephro.2017.02.003"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00240106"},{"issue":"10","key":"e_1_2_7_29_1","first-page":"Cd007004","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung EY","year":"2020","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14801","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14801","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:40:40Z","timestamp":1761885640000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/dom.14801"],"URL":"https:\/\/doi.org\/10.1111\/dom.14801","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14801\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14801\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14801\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14801\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14801\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14801\/v1\/review2","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"2022-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}